Novartis gets EU approval for Cushing's drug
ZURICH (Reuters) - Swiss drug maker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.
Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January.
Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.
- Tweet this
- Share this
- Digg this
- On eve of secession vote, UK's fate hangs on a divided Scotland |
- Analysis - Market calm over Scottish vote at odds with disaster warnings
- As many as 700 migrants feared drowned in Mediterranean
- UK earnings edge up, unemployment falls more than expected
- Gerrard lights up Anfield with last-gasp Liverpool winner